A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

What this study is about

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Who can join (things the study team will check)

✅ You may be able to join if…

• Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
• Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
• Progressive disease in the setting of medical or surgical castration.
• ECOG performance status 0 or 1, with a life expectancy of ≥12 months as assessed by the investigator.

🚫 You may not be able to join if…

• Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that make the participant inappropriate for the study.
• Known history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery.
• Clinically significant cardiovascular disease.
• Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure.
• Any history of myelodysplastic syndrome, acute myeloid leukemia, or any other prior malignancy with a few exceptions.
• Participants must be treatment naïve at the mCRPC stage, eg, no cytotoxic chemotherapy, radio-ligand therapy (i.e. 177Lu- PSMA-617), CDK4/6 inhibitors, 5-alpha reductase inhibitors for prostate cancer in any setting, androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment with the following exceptions:
  • Treatment with first-generation antiandrogen (ADT) agents, estrogens, progestins, cyproterone acetate;
  • Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion.
• Previous administration with an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is longer).
• Inadequate organ function.

Where this trial is running

• Ironwood Cancer & Research Centers, Chandler, Arizona, United States
• Ironwood Cancer & Research Centers, Gilbert, Arizona, United States
• Palo Verde Hematology Oncology, Glendale, Arizona, United States
• Ironwood Cancer & Research Centers, Glendale, Arizona, United States
• Ironwood Cancer & Research Centers, Goodyear, Arizona, United States
• Ironwood Cancer & Research Centers, Mesa, Arizona, United States
• Ironwood Cancer & Research Centers, Mesa, Arizona, United States
• Ironwood Cancer & Research Centers, Phoenix, Arizona, United States
• Ironwood Cancer & Research Centers, Scottsdale, Arizona, United States
• Highlands Oncology, Fayetteville, Arkansas, United States
• Arkansas Urology - Little Rock, Little Rock, Arkansas, United States
• Highlands Oncology, Rogers, Arkansas, United States

+ 228 more sites.

Who to contact

Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06629779.